MIT 6.S897 Machine Learning for Healthcare, Spring 2019
Instructor: David Sontag
View the complete course: https://ocw.mit.edu/6-S897S19
YouTube Playlist: https://www.youtube.com/playlist?list=PLUl4u3cNGP60B0PQXVQyGNdCyCTDU1Q5j

Prof. Sontag discusses aspects of disease progression modeling, including staging, subtyping, and multi-task and unsupervised learning. The goals are to determine the patient’s place in the disease trajectory and how treatment may affect progression.

License: Creative Commons BY-NC-SA
More information at https://ocw.mit.edu/terms
More courses at https://ocw.mit.edu

This video aims to educate undergraduate university students with at least one year of science background about how to disease progression and development is measured for ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease or motor neuron disease). Despite recent advances in research, there is currently no cure for ALS and much is still unknown about the disease. The number of individuals who die from ALS has increased to three per day in Canada. This video discusses ALS research relating to the measurement of disease progression.

Video by students from McMaster University’s Demystifying Medicine Seminar Series

Subscribe to the McMaster Demystifying Medicine YouTube channel: https://www.youtube.com/c/DemystifyingMedicine

This video is provided for general and educational information only. Please consult your health care provider for Information about your health.

Copyright McMaster University 2018

#DemystifyingMedicine #ALS

References

Armon, C., Graves, M.C., Moses, D., Forte, D.K. Sepulveda, L. Darby, S. & Smith, R. A. (2000). Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle & Nerve, 23, 874-882.

Armon, C. & Brandstater, M.E. (1999). Motor unit number estimate-based rates of progression of ALS predict patient survival. Muscle & Nerve, 22, 1571-1575.

Czaplinski, A., Yen, A.A. & Appel, S.H. (2006). Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. Journal of Neurology, Neurosurgery, and Psychiatry, 77, 390-392.

DeJesus-Hernandez, M., Mackenzie, I.R., Boeve, B.F., Boxer, A.L., Baker, M., Rutherford, N.J., […] & Rademakers, R. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-Linked FTD and ALS. Neuron, 72, 245-256.

Freischmidt, A., Wieland, T., Richter, B., Ruf, W., Schaeffer, V., Muller, K., […] & Weishaupt, J.H. (2015). Haploinsufficiency of TBK1 causes familial ALS and front-temporal dementia. Nature Neuroscience, 18, 631-636.

Simon, N.G., Turner, M. R., Vucic, S., Al-Chalabi, A., Shefner, J., Lomen-Hoerth, C. & Kiernan, M.C. (2014). Quantifying disease progression amyotrophic lateral sclerosis. Annals of Neurology, 76, 643-657.

Wong, P.C., Pardo, C.A., Borchelt, D.R., Lee, M.K., Copeland, N.G., Jenkins, J.A., […] & Price, D.L. (1995). An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron, 14, 1105-1116.
Video Rating: / 5

Share this page:

http://armandoh.org/

http://www.facebook.com/ArmandoHasudungan

Share this page:

📌 𝐅𝐨𝐥𝐥𝐨𝐰 𝐨𝐧 𝐈𝐧𝐬𝐭𝐚𝐠𝐫𝐚𝐦:- https://www.instagram.com/drgbhanuprakash
📌𝗝𝗼𝗶𝗻 𝗢𝘂𝗿 𝗧𝗲𝗹𝗲𝗴𝗿𝗮𝗺 𝗖𝗵𝗮𝗻𝗻𝗲𝗹 𝗛𝗲𝗿𝗲:- https://t.me/bhanuprakashdr
📌𝗦𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲 𝗧𝗼 𝗠𝘆 𝗠𝗮𝗶𝗹𝗶𝗻𝗴 𝗟𝗶𝘀𝘁:- https://linktr.ee/DrGBhanuprakash

WHAT ARE DISEASE-MODIFYING ANTIRHEUMATIC DRUGS?

DMARDs work to suppress the body’s overactive immune and/or inflammatory systems. They take effect over weeks or months and are not designed to provide immediate relief of symptoms.

Other medicines, such as pain relievers, nonsteroidal anti-inflammatory drugs (eg, ibuprofen or naproxen), and, sometimes, prednisone, are given to provide faster relief of ongoing symptoms. DMARDs are often used in combination with these medications to reduce the total amount of medication needed and to prevent damage to joints.

DISEASE-MODIFYING ANTIRHEUMATIC DRUGS — The choice of DMARD depends on a number of factors, including the stage and severity of the joint condition, the balance between possible side effects and expected benefits, and patient preference. Before treatment begins, the patient and clinician should discuss the benefits and risks of each type of therapy, including possible side effects and toxicities, dosing schedule, monitoring frequency, and expected results. Certain screening tests, including blood tests for past exposure to certain infections, may be needed before starting some of these medications.

In some cases, one DMARD is used. In others, more than one medication may be recommended. Sometimes a patient must try different medicines or combinations to find one that works best and that has the fewest side effects. A patient who does not respond completely to a single DMARD may be given a combination of DMARDs, such as methotrexate plus another medication.

The most common DMARDs are methotrexate, sulfasalazine, hydroxychloroquine, and leflunomide. Less frequently used medications include gold salts, azathioprine, and cyclosporine.
Video Rating: / 5

Disease modifying anti-rheumatic drugs (DMARDs); what you need to know before taking them. Talk to your healthcare team for more information.

Please find the iBook available for download here: https://itunes.apple.com/us/book/rheum-medi-info/id1123774842?ls=1&mt=11

Project credit
A Master’s Research Project submitted in conformity with the requirements for the degree of Master of Science in Biomedical Communications (MScBMC).
Offered through the Institute of Medical Sciences, Faculty of Medicine, University of Toronto in collaboration with Biomedical Communications, Department of Biology, University of Toronto Mississauga.

Copyright 2016 Marina Spyridis.

Committee members
Shelley Wall, AOCAD, MA, MScBMC, PhD, CMI
Assistant Professor, Biomedical Communications
Department of Biology
University of Toronto Mississauga

Shirley Tse, MD, FRCPC
Associate Professor, Department of Paediatrics
Faculty of Medicine
University of Toronto

Any material in this iBook may not be manipulated, reproduced or distributed without permission.

Comments: advertising treatments, of a negative nature, or unrelated to this video content will be removed. This is meant as an introductory educational tool for children, young adults and adults.

Share this page: